(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 93.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Meiragtx Holdings's revenue in 2025 is $37,917,000.On average, 2 Wall Street analysts forecast MGTX's revenue for 2025 to be $4,471,270,772, with the lowest MGTX revenue forecast at $1,235,673,247, and the highest MGTX revenue forecast at $7,706,868,297. On average, 2 Wall Street analysts forecast MGTX's revenue for 2026 to be $22,600,511,951, with the lowest MGTX revenue forecast at $22,533,338,308, and the highest MGTX revenue forecast at $22,667,685,594.
In 2027, MGTX is forecast to generate $14,696,145,098 in revenue, with the lowest revenue forecast at $14,696,145,098 and the highest revenue forecast at $14,696,145,098.